Dexmedetomidine
Neuralgia
Universidad Juárez Autónoma de TabascoSmall moleculePhase 4 / ApprovedActive
BBB
76/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 64/ 100
- Competitive Position
- 95/ 100
Competitive context
48 Active assets in the Neuralgia cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Midazolam Minia University | Phase 4 | BBB |
Lidocaine Ataturk University | Phase 4 | BBB |
(±)-2-(O-CHLOROPHENYL)-2-(METHYLAMINO)CYCLOHEXANONE Margaux M. Salas, PhD | Phase 4 | BBB |
Marcaine Medipol University | Phase 4 | BBB |
Capsaicin University Hospital, Clermont-Ferrand | Phase 4 | BBB |
View all 50 →
Same molecule, other indications
Dexmedetomidine is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →